L 759274

Drug Profile

L 759274

Alternative Names: NK1 antagonist - Merck; Substance P antagonist - Merck

Latest Information Update: 20 Jun 2012

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antidepressants
  • Mechanism of Action Neurokinin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Major depressive disorder

Most Recent Events

  • 31 Dec 2009 Development discontinued for Major depressive disorder before 2009 after NDR for >3 years
  • 19 Mar 2004 A study has been added to the Affective disorders therapeutic trials section
  • 06 Oct 2003 A study has been added to the adverse events and Affective disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top